Consortium Partners
|
The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers for use in research, therapeutic and diagnostic development and approval, and clinical practice. All public- and private-sector partners are involved in consortium governance and contribute their scientific and technical expertise as advisors to the effort. In addition, public partners--NIH, FDA, CMS, and other federal agencies--may contribute financial resources and manage the conduct of projects under the consortium. Private-sector partners--corporations, non-profit organizations and associations, and advocacy groups--provide both financial contributions to help support the consortium's overall operations and may also fund individual projects conducted by the consortium. Through their generous commitments of financial resources and scientific insights to this initiative, The Biomarkers Consortium partners help ensure that the consortium lives up to its promise of speeding disease-specific research and ensuring that safe, innovative, and effective medicines and diagnostics are expeditiously developed to address healthcare needs, improve medical care, and promote and improve public health. Learn more about Consortium partners: Government partners The Foundation for NIH is actively seeking additional partners, and encourages other corporations, non-profit and associations, advocacy organizations, and philanthropic organizations to participate in The Biomarkers Consortium. For further information about supporting The Biomarkers Consortium, please contact David Lee at .
|
|

